New PSA Review Finds Modest Benefit, but Not Routine Screening

A major Cochrane review updated in May 2026 found that PSA-based screening likely lowers the chance of dying from prostate cancer, but by a modest amount. In the review, screening was linked to about 2 fewer prostate-cancer deaths per 1,000 men screened over up to 23 years. That is not a signal that every man should be screened. It is a reason for many men, especially ages 55 to 69, to revisit the conversation.

What PSA screening is, and why it has been debated

The PSA test is a blood test used to look for possible prostate cancer in men who do not have symptoms. The problem is that a high PSA does not automatically mean a dangerous cancer. It can lead to repeat testing, biopsy, and the diagnosis of slow-growing cancers that might never have caused symptoms or shortened life.

That tradeoff has shaped the debate for years. Screening may help some men avoid death from prostate cancer, but it can also expose others to overdiagnosis, overtreatment, and treatment side effects such as urinary incontinence, erectile dysfunction, and bowel problems.

What the new review found

The updated Cochrane review examined six randomized trials including 789,086 men in Canada, Europe, and the United States. Most participants were White. Men were 45 to 80 years old, and follow-up ranged from 3.2 to 23 years.

The clearest finding was a small reduction in prostate-cancer deaths. The review also estimated 36 more prostate-cancer diagnoses and 34 more localized-cancer diagnoses per 1,000 men screened, along with 5 fewer metastatic cancers per 1,000 men screened. In plain language, screening likely finds more cancers overall, including some that may never have become dangerous, while also preventing a smaller number of advanced cases and deaths.

The review also said screening may reduce death from any cause, but that finding was less certain. The authors said they were moderately confident in the main prostate-cancer mortality finding, which was driven largely by one large, long-running European trial. They also said the underlying studies provided limited information about common biopsy and treatment harms, so the benefit estimate is clearer than the harms estimate.

What current U.S. guidance still says

Current U.S. guidance has not shifted to routine screening for all men. The CDC and the U.S. Preventive Services Task Force say men ages 55 to 69 should make an individual decision about PSA screening after discussing benefits and harms with a clinician. The USPSTF recommends against routine PSA-based screening for men 70 and older.

That means shared decision-making remains the standard. Age matters, but so do family history, race, overall health, life expectancy, and how a person feels about the possibility of further testing or treatment after an abnormal result. Screening is meant for men without prostate-cancer symptoms, not as a substitute for medical evaluation of new concerns.

Who may want to revisit the discussion now

For average-risk men, the new evidence is most relevant to ages 55 to 69, because that is the group U.S. guidance already identifies as the clearest candidates for an individualized screening decision.

Some men may want to start that discussion earlier because their risk is higher. The American Cancer Society says men at average risk should have a chance to discuss screening at age 50 if they are expected to live at least 10 more years. It suggests starting at age 45 for African American men and men with a first-degree relative diagnosed before age 65, and at age 40 for men with more than one first-degree relative diagnosed early.

The review does not prove exactly which higher-risk groups gain the most benefit, partly because the trial populations were not very diverse. Still, it strengthens the case for not dismissing PSA screening as having no benefit at all.

Coverage and cost context

Coverage can make the decision easier to act on, but coverage is not the same as a recommendation. Medicare Part B covers a PSA blood test once every 12 months for men over 50 at no cost for the test itself. Medicare also covers digital rectal exams once every 12 months for eligible beneficiaries, although cost-sharing can apply to the exam and related clinician services.

Even when the screening blood test is covered, extra costs can still arise after an abnormal result or if a clinician recommends services that are not covered or are done more often than Medicare allows. That can matter for follow-up visits, additional testing, or procedures.

Bottom line

The new review makes the evidence for PSA screening look somewhat stronger than it did in older summaries. But it does not turn PSA testing into a one-size-fits-all recommendation. For men 55 to 69, and for some higher-risk men considering an earlier conversation, the most reasonable next step is to ask a clinician how the modest potential benefit compares with the possible harms in their own situation.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.